A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

@article{Flaherty2008API,
  title={A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.},
  author={Keith T Flaherty and Jocelyn Schiller and Lynn Mara Schuchter and Glenn X Liu and David A Tuveson and Maryann Redlinger and Chetan Lathia and Chenghua Xia and Oana Petrenciuc and Sunil Hingorani and Michael A. Jacobetz and Patricia A Van Belle and David W. Elder and Marcia S. Brose and Barbara L. Weber and Mark R Albertini and Peter J. O'dwyer},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 15},
  pages={
          4836-42
        }
}
PURPOSE This study evaluated the safety, maximum tolerated dose, pharmacokinetics, and antitumor activity of sorafenib, a multikinase inhibitor, combined with paclitaxel and carboplatin in patients with solid tumors. PATIENTS AND METHODS Thirty-nine patients with advanced cancer (24 with melanoma) received oral sorafenib 100, 200, or 400 mg twice daily on days 2 to 19 of a 21-day cycle. All patients received carboplatin corresponding to AUC6 and 225 mg/m(2) paclitaxel on day 1… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 62 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Inhibi - tion of tumor endothelial ERK activation , angiogenesis , and tumor growth by sorafenib ( BAY 43 - 9006 )

  • DA Murphy, LassouedW Makonnen S
  • AmJPathol
  • 2006

Similar Papers

Loading similar papers…